|
| 36279715 | Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells. | Transl Oncol | 2023 |
| 37559718 | Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM. | Front Immunol | 2023 |
| 37165840 | Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. | Haematologica | 2023 |
| 36599350 | CD8<sup>+</sup> TÂ cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. | Cell Rep Med | 2023 |
| 36595569 | Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. | Clin Cancer Res | 2023 |
| 36450626 | Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2023 |
| 34864148 | Quantification of Glomerular Structural Lesions: Associations With Clinical Outcomes and Transcriptomic Profiles in Nephrotic Syndrome. | Am J Kidney Dis | 2022 |
| 35435276 | Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. | Prostate | 2022 |
| 36033464 | Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling. | Front Oncol | 2022 |
| 35045765 | A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. | Leuk Lymphoma | 2022 |
| 34940781 | Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. | JAMA Oncol | 2022 |
| 33157048 | Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. | Cancer Cell | 2020 |
| 31992571 | Systems Biology and Kidney Disease. | Clin J Am Soc Nephrol | 2020 |
| 30294956 | An integrative systems biology approach for precision medicine in diabetic kidney disease. | Diabetes Obes Metab | 2018 |
| 30074515 | Systems biology approaches to identify disease mechanisms and facilitate targeted therapy in the management of glomerular disease. | Curr Opin Nephrol Hypertens | 2018 |
| 25893298 | Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. | Oncogene | 2016 |
| 27729437 | Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes. | G3 (Bethesda) | 2016 |
| 27016234 | Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. | Gynecol Oncol | 2016 |
| 25468909 | Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. | J Biol Chem | 2015 |
| 24504028 | Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. | Sci Rep | 2014 |
| 25269487 | Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. | J Natl Cancer Inst | 2014 |
| 25167228 | KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. | Br J Cancer | 2014 |
| 23493311 | The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. | Mol Cancer Ther | 2013 |
| 23898052 | PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. | Anticancer Res | 2013 |
| 23405260 | Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. | PLoS One | 2013 |
| 23571109 | Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. | Hum Mol Genet | 2013 |
| 21637838 | Identification of novel targets of CSL-dependent Notch signaling in hematopoiesis. | PLoS One | 2011 |
| 19348643 | Inferring direct regulatory targets of a transcription factor in the DREAM2 challenge. | Ann N Y Acad Sci | 2009 |
| 12874036 | Functional analysis of the EWS/ETS target gene uridine phosphorylase. | Cancer Res | 2003 |
| 12414635 | MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. | Cancer Res | 2002 |